Genedrive (GDR) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Nov 2023 07:00 AM
RNS
Notice of Results
20 Oct 2023 10:52 AM
RNS
Total Voting Rights
28 Sep 2023 12:35 PM
RNS
c£1.2m grant awarded
21 Sep 2023 02:39 PM
RNS
Application for listing & total voting rights
11 Sep 2023 02:17 PM
RNS
Board changes
06 Sep 2023 07:00 AM
RNS
UKCA marking achieved for new CYP2C19 test
04 Aug 2023 04:00 PM
RNS
Total Voting Rights
05 Jul 2023 09:11 AM
RNS
Equity Prepayment Facility drawdown
16 Jun 2023 02:28 PM
RNS
Holding(s) in Company
16 Jun 2023 07:00 AM
RNS
Multi-partner grant awarded
02 Jun 2023 12:25 PM
RNS
Equity Prepayment Facility drawdown
31 May 2023 07:00 AM
RNS
Block Listing Returns
19 May 2023 07:00 AM
RNS
NICE recommends CYP2C19 genotyping
15 May 2023 05:56 PM
RNS
Block Listing Application to AIM
11 May 2023 11:58 AM
RNS
Result of General Meeting
24 Apr 2023 11:54 AM
RNS
Publication of Circular and Notice of GM
24 Apr 2023 11:54 AM
RNS
Publication of Circular and Notice of GM
11 Apr 2023 05:44 PM
RNS
Holding(s) in Company
06 Apr 2023 08:00 AM
RNS
Total Voting Rights
31 Mar 2023 06:32 PM
RNS
£5 million Equity Prepayment Facility
31 Mar 2023 06:32 PM
RNS
Half-year Report
30 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
30 Mar 2023 09:05 AM
RNS
Second Price Monitoring Extn
30 Mar 2023 09:00 AM
RNS
Price Monitoring Extension
30 Mar 2023 07:00 AM
RNS
Positive final recommendation by NICE
23 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
20 Mar 2023 07:00 AM
RNS
Commence of roll out in Greater Manchester
09 Feb 2023 02:05 PM
RNS
Second Price Monitoring Extn
09 Feb 2023 02:00 PM
RNS
Price Monitoring Extension
09 Feb 2023 09:05 AM
RNS
Second Price Monitoring Extn
09 Feb 2023 09:00 AM
RNS
Price Monitoring Extension
09 Feb 2023 07:00 AM
RNS
AIHL test preliminary recommendation by NICE
27 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
27 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
26 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
26 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
26 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
26 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
25 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
25 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
19 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
19 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
29 Dec 2022 06:10 PM
RNS
Result of AGM
05 Dec 2022 07:00 AM
RNS
Notice of AGM
30 Nov 2022 07:00 AM
RNS
Block Listing Six Monthly Return
21 Nov 2022 07:00 AM
RNS
Audited Final Results
14 Nov 2022 07:00 AM
RNS
Notice of Results
24 Oct 2022 07:00 AM
RNS
Grant of options
05 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
05 Oct 2022 04:35 PM
RNS
Price Monitoring Extension

Genedrive plc is a medical equipment company based in Manchester, UK that develops and sells point-of-care molecular diagnostic platforms. Their products are used in healthcare settings, particularly in emergency medicine, for patient stratification and disease detection. Genedrive's goal is to improve clinical outcomes with easy-to-use tests. 

 Genedrive's major products include:
Genedrive CYP2C19 ID Kit: A rapid test that establishes metaboliser status in time-critical settings
Genedrive MT-RNR1 ID Kit: The world's first point-of-care genetic test to reduce the risk of aminoglycoside induced hearing loss

Genedrive was founded on contract research services for pharmaceutical and biotech companies, and was originally named Epistem Holdings Inc. when it was floated on the London AIM market in 2007. The company was renamed genedrive plc in 2016 to reflect its new focus on molecular diagnostics, and divested its contract research services divisions in 2018.

GDR share price launched at 129p in 2007. 

UK 100

Latest directors dealings